Inositols in PCOS
Abstract
:1. Overview of PCOS Pathogenesis
1.1. Polycystic Ovarian Syndrome and Insulin Resistance
1.2. Polycystic Ovarian Syndrome and Sex-Hormonal Imbalance
1.3. Polycystic Ovarian Syndrome and Ovarian Changes
2. Inostols—Biological Role in Glucose Metabolism and Ovarian Function
3. Inositols and Insulin Resistance in PCOS
4. Inositols and Other Metabolic Abnormalities in PCOS
5. Inositols and Hyperandrogenism in PCOS
6. Inositols and Menstrual Disturbances/Ovulation in PCOS
7. Inositols and Gestational Diabetes in PCOS
8. Inositols in Combination with Other Compounds in PCOS Treatment
9. Resistance to Myoinositol in PCOS Patients
10. Conclusions
Funding
Conflicts of Interest
References
- Azziz, R.; Carmina, E.; Dewailly, D.; Diamanti-Kardarakis, E.; Escobar-Morreale, H.F.; Futterweit, W.; Janssen, O.E.; Legro, R.S.; Norman, R.J.; Taylor, A.E.; et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 2006, 91, 4237–4245. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teede, H.J.; Deeks, A.; Moran, L.J. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010, 8, 41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aversa, A.; La Vignera, S.; Rago, R.; Gambineri, A.; Nappi, R.E.; Calogero, A.E.; Ferlin, A. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Front. Endocrinol. 2020, 11, 516. [Google Scholar] [CrossRef] [PubMed]
- Usadi, R.S.; Legro, R.S. Reproductive impact of polycystic ovary syndrome. Curr. Opin. Endocrinol. Diabetes Obes. 2012, 19, 505–511. [Google Scholar] [CrossRef] [PubMed]
- Moran, L.; Gibson-Helm, M.; Teede, H.; Deeks, A. Polycystic ovary syndrome: A biopsychosocial understanding in young women to improveknowledge and treatment options. J. Psychosom. Obstet. Gynecol. 2010, 31, 24–31. [Google Scholar] [CrossRef]
- Deeks, A.; Gibson-Helm, M.; Teede, H. Is having polycystic ovary syndrome (PCOS) a predictor of poor psychological function including depression and anxiety. Hum. Reprod. 2011, 26, 1399–1407. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teede, H.J.; Misso, M.L.; Costello, M.F.; Dokras, A.; Laven, J.; Moran, L.; Piltonen, T.; Norman, R.J. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 2018, 110, 364–379. [Google Scholar] [CrossRef] [Green Version]
- Chang, J.; Azziz, R.; Legro, R.; Dewailly, D.; Franks, S.; Tarlatzis, R.; Fauser, B.; Balen, A.; Bouchard, P.; Dalgien, E.; et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004, 81, 19–25. [Google Scholar] [CrossRef]
- Goodman, N.F.; Cobin, R.H.; Futterweit, W.; Glueck, J.S.; Legro, R.S.; Carmina, E.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome–part 1. Endocr. Pract. 2015, 21, 1291–1300. [Google Scholar] [CrossRef] [Green Version]
- Rosenfield, R.L.; Ehrmann, D.A. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr. Rev. 2016, 37, 467–520. [Google Scholar] [CrossRef]
- Ferreira, S.R.; Motta, A.B. Uterine Function: From Normal to Polycystic Ovarian Syndrome Alterations. Curr. Med. Chem. 2018, 25, 1792–1804. [Google Scholar] [CrossRef] [PubMed]
- Gambineri, A.; Laudisio, D.; Marocco, C.; Radellini, S.; Colao, A.; Savastano, S. Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Female infertility: Which role for obesity? Int. J. Obes. Suppl. 2019, 9, 65–72. [Google Scholar] [CrossRef] [PubMed]
- Astapova, O.; Minor, B.M.N.; Hammes, S.R. Physiological and Pathological Androgen Actions in the Ovary. J. Endocrinol. 2019, 160, 1166–1174. [Google Scholar] [CrossRef] [PubMed]
- Legro, R.S.; Kunselman, A.R.; Dodson, W.; Dunaif, A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 1999, 84, 165–169. [Google Scholar] [CrossRef]
- Legro, R.S.; Finegood, D.; Dunaif, A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1998, 83, 2694–2698. [Google Scholar] [CrossRef]
- Ducluzeau, P.; Cousin, P.; Malvoisin, E.; Bornet, H.; Vidal, H.; Laville, M.; Pugeat, M. Glucose-to-Insulin Ratio Rather than Sex Hormone-Binding Globulin and Adiponectin Levels Is the Best Predictor of Insulin Resistance in Nonobese Women with Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 2003, 88, 3626–3631. [Google Scholar] [CrossRef] [Green Version]
- Fulgeshu, A.; Angioni, S.; Portoghese, E.; Milano, F.; Batetta, B.; Paoletti, A.; Melis, G. Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome. Fertil. Steril. 2006, 86, 398–404. [Google Scholar] [CrossRef]
- McLaughlin, T.; Allison, G.; Abbasi, F.; Lamendola, C.; Reaven, G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004, 53, 495–499. [Google Scholar] [CrossRef]
- Dunaif, A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr. Rev. 1997, 18, 774–800. [Google Scholar]
- Gateva, A.; Kamenov, Z. Cardiovascular Risk Factors in Bulgarian Patients with Polycystic Ovary Syndrome and/or Obesity. Obstet. Gynecol. Int. 2012, 2012, 1–11. [Google Scholar] [CrossRef]
- Morin-Papunen, L.C.; Vauhkonen, I.; Koivunen, R.M.; Ruokonen, A.; Tapanainen, J.S. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum. Reprod. 2000, 15, 1266–1274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ciaraldi, T.P.; Morales, A.J.; Hickman, M.G.; Odom-Ford, M.; Olefsky, J.M.; Yen, S.S. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J. Clin. Endocrinol. Metab. 1997, 82, 1421–1425. [Google Scholar] [CrossRef] [PubMed]
- Vigil, P.; Contreras, P.; Alvarado, J.; Godoy, A.; Salgado, A.; Cortes, M. Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome. Hum. Reprod. 2007, 22, 2974–2980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gateva, A.; Kamenov, Z. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012, 164, 161–166. [Google Scholar] [CrossRef]
- Apridonidze, T.; Essah, P.A.; Iuorno, M.J.; Nestler, J.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2005, 90, 1929–1935. [Google Scholar] [CrossRef] [Green Version]
- Norman, R.J.; Davies, M.J.; Lord, J.; Moran, L.J. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol. Metab. 2002, 13, 251–257. [Google Scholar] [CrossRef]
- Yildiz, B.O.; Knochenhauer, E.S.; Azziz, R. Impact of Obesity on the Risk for Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 2008, 93, 162–168. [Google Scholar] [CrossRef] [Green Version]
- Gambineri, A.; Pelusi, C.; Vicennati, V.; Pagotto, U.; Pasquali, R. Obesity and the polycystic ovary syndrome. Int. J. Obes. Relat. Metab. Disord. 2002, 26, 883–896. [Google Scholar] [CrossRef] [Green Version]
- Escobar-Morreale, H.; San Millan, J. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol. Metabol. 2007, 18, 266–272. [Google Scholar]
- Diamanti-Kandarakis, E.; Panidis, D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): A prospective study of 634 women with PCOS. Clin. Endocrinol. 2007, 67, 735–742. [Google Scholar] [CrossRef]
- Conway, G.S.; Jacob, H.S.; Holly, J.M.; Wass, J.A. Effects of lute inizing hormone, insulin, insulin-like growth factor-I and ins ulin-like growth fac tor small bind ing protein I in the polycystic ovary syndrome. Clin. Endocrinol. 1990, 33, 593–603. [Google Scholar] [CrossRef] [PubMed]
- Robinson, S.; Kiddy, D.; Gelding, S.V.; Willis, D.; Niththyananthan, R.; Bush, A.; Johnston, D.G.; Franks, S. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin. Endocrinol. 1993, 39, 351–355. [Google Scholar] [CrossRef] [PubMed]
- Nestler, J.E.; Jakubowicz, D.J. Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary Syndrome. N. Engl. J. Med. 1996, 335, 617–623. [Google Scholar] [CrossRef] [PubMed]
- Nestler, J.E.; Jakubowicz, D.J. Lean Women with Polycystic Ovary Syndrome Respond to Insulin Reduction With Decreases in Ovarian P450c17 alpha Activity and Serum Androgens. Obstet. Gynecol. Surv. 1998, 53, 289–291. [Google Scholar] [CrossRef]
- Cara, J.F.; Rosenfield, R.L. Insulin-Like Growth Factor I and Insulin Potentiate Luteinizing Hormone-Induced Androgen Synthesis by Rat Ovarian Thecal-Interstitial Cells. Endocrinology 1988, 123, 733–739. [Google Scholar] [CrossRef] [PubMed]
- Ek, I.; Arner, P.; Bergqvist, A.; Carlström, K.; Wahrenberg, H. Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: A possible link to insulin resistance? J. Clin. Endocrinol. Metab. 1997, 82, 1147–1153. [Google Scholar] [PubMed] [Green Version]
- Nestler, J.E.; Powers, L.P.; Matt, D.W.; Steingold, K.A.; Plymate, S.R.; Rittmaster, R.S.; Clore, J.N.; Blackard, W.G. A Direct Effect of Hyperinsulinemia on Serum Sex Hormone-Binding Globulin Levels in Obese Women with the Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 1991, 72, 83–89. [Google Scholar] [CrossRef]
- Nestler, J.E.; Jakubowicz, D.J.; De Vargas, A.F.; Brik, C.; Quintero, N.; Medina, F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 1998, 83, 2001–2005. [Google Scholar]
- Dunaif, A.; Segal, K.R.; Futterweit, W.; Dobrjansky, A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38, 1165–1174. [Google Scholar] [CrossRef]
- Dunaif, A.; Segal, K.R.; Shelley, D.R.; Green, G.; Dobrjansky, A.; Licholai, T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992, 41, 1257–1266. [Google Scholar] [CrossRef]
- Willis, D.; Mason, H.; Gilling-Smith, C.; Franks, S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J. Clin. Endocrinol. Metab. 1996, 81, 302–309. [Google Scholar] [PubMed] [Green Version]
- Baillargeon, J.P.; Diamanti-Kandarakis, E.; Ostlund, R.E., Jr.; Apridonidze, T.; Iuorno, M.J.; Nestler, J.E. Altered D-chiro-inositol urinary clearance in women with polycystic ovarian syndrome. Diabetes Care 2006, 29, 300–305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rice, S.; Christoforidis, N.; Gadd, C.; Nikolaou, D.; Seyani, L.; Donaldson, A.; Margara, R.; Hardy, K.; Franks, S. Impaired insulindependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum. Reprod. 2005, 20, 373–381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rebar, R.W.; Judd, H.L.; Yen, S.S.; Rakoff, J.S.; Vandenberg, G.; Naftolin, F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J. Clin. Investig. 1976, 57, 1320–1329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Conway, G.S.; Honour, J.W.; Jacobs, H.S. Heterogeneity of the polycystic ovary syndrome: Clinical, endocrine and ultrasound features in 556 patients. Clin. Endocrinol. 1989, 30, 459–470. [Google Scholar] [CrossRef] [PubMed]
- Quigley, M.; Rakoff, J.; Yen, S.S.C. Increased luteinising hormone sensitivity to dopamine inhibition in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1981, 52, 231. [Google Scholar] [CrossRef] [PubMed]
- Cumming, D.C.; Reid, R.L.; Quigley, M.E.; Rebar, R.W.; Yen, S.S.C. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome. Clin. Endocrinol. 1984, 20, 643–648. [Google Scholar] [CrossRef]
- Barbieri, R.L.; Makris, A.; Randall, R.W.; Daniels, G.; Kistner, R.W.; Ryan, K.J. Insulin Stimulates Androgen Accumulation in Incubations of Ovarian Stroma Obtained from Women with Hyperandrogenism. J. Clin. Endocrinol. Metab. 1986, 62, 904–910. [Google Scholar] [CrossRef]
- Dunkel, L.; Sorva, R.; Voutilainen, R. Low levels of sex hormone-binding globulin in obese children. J. Pediatr. 1985, 107, 95–97. [Google Scholar] [CrossRef]
- Adashi, E.Y.; Hsueh, A.J.; Yen, S.S. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 1981, 108, 1441–1449. [Google Scholar] [CrossRef]
- Soldani, R.; Cagnacci, A.; Yen, S.S. Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro. Eur. J. Endocrinol. 1994, 131, 641–645. [Google Scholar] [CrossRef] [PubMed]
- Poretsky, L.; Glover, B.; Laumas, V.; Kalin, M.; Dunaif, A. The Effects of Experimental Hyperinsulinemia on Steroid Secretion, Ovarian [125 I]Insulin Binding, and Ovarian [125 I]Insulin-Like Growth-Factor I Binding in the Rat. Endocrinology 1988, 122, 581–585. [Google Scholar] [CrossRef] [PubMed]
- Poretsky, L.; Cataldo, N.A.; Rosenwaks, Z.; Giudice, L.C. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 1999, 20, 535–582. [Google Scholar] [CrossRef]
- Franks, S.; Mason, H.; Willis, D. Follicular dynamics in the polycystic ovary syndrome. Mol. Cell. Endocrinol. 2000, 163, 49–52. [Google Scholar] [CrossRef]
- Carmina, E.; Rosato, F.; Jannì, A.; Rizzo, M.; Longo, R.A. Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred because of Clinical Hyperandrogenism. J. Clin. Endocrinol. Metab. 2006, 91, 2–6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dunaif, A.; Graf, M.; Mandeli, J.; Laumas, V.; Dobrjansky, A. Characterization of Groups of Hyperaiidrogenic Women with Acanthosis Nigricans, Impaired Glucose Tolerance, and/or Hyperinsulinemia. J. Clin. Endocrinol. Metab. 1987, 65, 499–507. [Google Scholar] [CrossRef]
- Barber, T.M.; Wass, J.A.H.; McCarthy, M.I.; Franks, S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: Implications for the management of polycystic ovary syndrome. Clin. Endocrinol. 2007, 66, 513–517. [Google Scholar] [CrossRef]
- Taylor, A.E.; McCourt, B.; Martin, K.A.; Anderson, E.J.; Adams, J.M.; Schoenfeld, D.; Hall, J.E. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1997, 82, 2248–2256. [Google Scholar] [CrossRef]
- Bevilacqua, A.; Bizzarri, M. Inositols in Insulin Signaling and Glucose Metabolism. Int. J. Endocrinol. 2018, 2018, 1–8. [Google Scholar] [CrossRef] [Green Version]
- Halsted, C.H. Handbook of Vitamins: Nutritional, Biochemical, and Clinical Aspects. J. Nutr. 1987, 117, 397. [Google Scholar] [CrossRef]
- Beemster, P.; Groenen, P.; Steegers-Theunissen, R. Involvement of Inositol in Reproduction. Nutr. Rev. 2002, 60, 80–87. [Google Scholar] [CrossRef] [PubMed]
- Chukwuma, C.I.; Ibrahim, M.A.; Islam, S. Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: A dual approach study. J. Physiol. Biochem. 2016, 72, 791–801. [Google Scholar] [CrossRef] [PubMed]
- Cammarata, P.R.; Chen, H.Q.; Yang, J.; Yorio, T. Modulation of myo-[3H]inositol uptake by glucose and sorbitol in cultured bovine lens epithelial cells. II. Characterization of high- and low-affinity myo-inositol transport sites. Investig. Ophthalmol. Vis. Sci. 1992, 33, 3572–3580. [Google Scholar]
- Kollros, P.E.; Goldstein, G.W.; Betz, A.L. Myo-inositol transport into endothelial cells derived from nervous system microvessels. Brain Res. 1990, 511, 259–264. [Google Scholar] [CrossRef] [Green Version]
- Unfer, V.; Nestler, J.E.; Kamenov, Z.A.; Prapas, N.; Facchinetti, F. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. Int. J. Endocrinol. 2016, 2016, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Facchinetti, F.; Appetecchia, M.; Aragona, C.; Bevilacqua, A.; Espinola, M.S.B.; Bizzarri, M.; D’Anna, R.; Dewailly, D.; Diamanti-Kandarakis, E.; Marín, I.H.; et al. Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: A further help for human reproduction and beyond. Expert Opin. Drug Metab. Toxicol. 2020, 16, 255–274. [Google Scholar] [CrossRef] [PubMed]
- Cabrera-Cruz, H.; Oróstica, L.; Plaza-Parrochia, F.; Torres-Pinto, I.; Romero, C.; Vega, M. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. Am. J. Physiol. Metab. 2020, 318, 237–248. [Google Scholar] [CrossRef] [PubMed]
- Nestler, J.E.; Jakubowicz, D.; Reamer, P.; Gunn, R.D.; Allan, G. Ovulatory and metabolic effects of D-chiroinositol in the polycystic ovary syndrome. N. Engl. J. Med. 1999, 340, 1314–1320. [Google Scholar] [CrossRef] [Green Version]
- Unfer, V.; Carlomagno, G.; Papaleo, E.; Vailati, S.; Candiani, M.; Baillargeon, J.-P. Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod. Sci. 2014, 21, 854–858. [Google Scholar] [CrossRef]
- Facchinetti, F.; Dante, G.; Neri, I. The Ratio of MI to DCI and Its Impact in the Treatment of Polycystic Ovary Syndrome: Experimental and Literature Evidences. Front. Gynecol. Endocrinol. 2016, 3, 103–109. [Google Scholar] [CrossRef]
- Unfer, V.; DiNicola, S.; Laganà, A.S.; Bizzarri, M. Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS. Int. J. Mol. Sci. 2020, 21, 7157. [Google Scholar] [CrossRef] [PubMed]
- Kalra, B.; Kalra, S.; Sharma, J.B. The inositols and polycystic ovary syndrome. Indian J. Endocrinol. Metab. 2016, 20, 720–724. [Google Scholar] [CrossRef] [PubMed]
- Carlomagno, G.; Unfer, V.; Roseff, S. The D-chiro-inositol paradox in the ovary. Fertil. Steril. 2011, 95, 2515–2516. [Google Scholar] [CrossRef] [PubMed]
- Laganà, A.S.; Rossetti, P.; Buscema, M.; La Vignera, S.; Condorelli, R.A.; Gullo, G.; Granese, R.; Triolo, O. Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. Int. J. Endocrinol. 2016, 2016, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Sortino, M.A.; Salomone, S.; Carruba, M.O.; Drago, F. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols. Front. Pharmacol. 2017, 8, 341. [Google Scholar] [CrossRef]
- Iuorno, M.J.; Nestler, J.E. Insulin-lowering drugs in polycystic ovary syndrome. Obstet. Gynecol. Clin. North. Am. 2001, 28, 153–164. [Google Scholar] [CrossRef]
- Donà, G.; Sabbadin, C.; Fiore, C.; Bragadin, M.; Giorgino, F.L.; Ragazzi, E.; Clari, G.; Bordin, L.; Armanini, D. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur. J. Endocrinol. 2012, 166, 703–710. [Google Scholar] [CrossRef] [Green Version]
- Zacchè, M.M.; Caputo, L.; Filippis, S.; Zacchè, G.; Dindelli, M.; Ferrari, A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol. Endocrinol. 2009, 25, 508–513. [Google Scholar] [CrossRef]
- Genazzani, A.D.; Lanzoni, C.; Ricchieri, F.; Jasonni, V.M. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweith patients with polycystic ovary syndrome. Gynecol. Endocrinol. 2008, 24, 139–144. [Google Scholar] [CrossRef]
- Minozzi, M.; Costantino, D.; Guaraldi, C.; Unfer, V. The effect of a combination therapy with myo-inositol and combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine and clinical parameterd in polycystic ovarian syndrome. Gynecol. Endocrinol. 2011, 27, 920–924. [Google Scholar] [CrossRef]
- Artini, P.G.; Di Berardino, O.M.; Papini, F.; Genazzani, A.D.; Simi, G.; Ruggiero, M.; Cela, V. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol. Endocrinol. 2013, 29, 375–379. [Google Scholar] [CrossRef] [PubMed]
- Benelli, E.; Del Ghianda, S.; Di Cosmo, C.; Tonacchera, M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int. J. Endocrinol. 2016, 2016, 1–5. [Google Scholar] [CrossRef] [Green Version]
- Unfer, V.; Facchinetti, F.; Orrù, B.; Giordani, B.; Nestler, J. Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocr. Connect. 2017, 6, 647–658. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zeng, L.; Yang, K. Effectiveness of myoinositol for polycystic ovary syndrome: A systematic review and meta-analysis. Endocrinology 2017, 59, 30–38. [Google Scholar] [CrossRef] [PubMed]
- De Diego, M.V.; Gómez-Pardo, O.; Groar, J.K.; López-Escobar, A.; Martín-Estal, I.; Castilla-Cortazar, I.; Rodríguez-Zambrano, M. Ángel Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: A preliminary study. Arch. Gynecol. Obstet. 2020, 302, 1169–1179. [Google Scholar] [CrossRef]
- Facchinetti, F.; Orrù, B.; Grandi, G.; Unfer, V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): A meta-analysis of randomized clinical trials. Gynecol. Endocrinol. 2019, 35, 198–206. [Google Scholar] [CrossRef]
- Shokrpour, M.; Foroozanfard, F.; Ebrahimi, F.A.; Vahedpoor, Z.; Aghadavod, E.; Ghaderi, A.; Asemi, Z. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: A randomized controlled clinical trial. Gynecol. Endocrinol. 2019, 35, 406–411. [Google Scholar] [CrossRef]
- Agrawal, A.; Mahey, R.; Kachhawa, G.; Khadgawat, R.; Vanamail, P.; Kriplani, A. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: Randomized controlled trial. Gynecol. Endocrinol. 2019, 35, 511–514. [Google Scholar] [CrossRef]
- Pkhaladze, L.; Barbakadze, L.; Kvashilava, N. Myo-Inositol in the Treatment of Teenagers Affected by PCOS. Int. J. Endocrinol. 2016, 2016, 1–6. [Google Scholar] [CrossRef] [Green Version]
- Gerli, S.; Papaleo, E.; Ferrari, A.; Di Renzo, G.C. Randomized, double blind placebo-controlled trial: Effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur. Rev. Med. Pharmacol. Sci. 2007, 11, 347–356. [Google Scholar]
- Genazzani, A.D.; Prati, A.; Santagni, S.; Ricchieri, F.; Chierchia, E.; Rattighieri, E.; Campedelli, A.; Simoncini, T.; Artini, P.G. Differential insulin response to myo-inositol administration in obese polycystic ovarian syndrome patients. Gynecol. Endocrinol. 2012, 28, 969–973. [Google Scholar] [CrossRef] [PubMed]
- Nordio, M.; Proietti, E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur. Rev. Med. Pharmacol. Sci. 2012, 16, 575–581. [Google Scholar] [PubMed]
- Minozzi, M.; Nordio, M.; Pajalich, R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 537–540. [Google Scholar] [PubMed]
- Le Donne, M.; Metro, D.; Alibrandi, A.; Papa, M.; Benvenga, S. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 2293–2301. [Google Scholar]
- Januszewski, M.; Issat, T.; Jakimiuk, A.A.; Santor-Zaczynska, M.; Jakimiuk, A.J. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol. Polska 2019, 90, 7–10. [Google Scholar] [CrossRef]
- Minozzi, M.; D’Andrea, G.; Unfer, V. Treatment of hirsutism with myo-inositol: A prospective clinical study. Reprod. Biomed. 2008, 17, 579–582. [Google Scholar] [CrossRef]
- Ozay, A.C.; Ozay, O.E.; Okyay, R.E.; Cagliyan, E.; Kume, T.; Gulekli, B. Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women. Int. J. Endocrinol. 2016, 2016, 1–8. [Google Scholar] [CrossRef] [Green Version]
- Regidor, P.-A.; Schindler, A.E.; Lesoine, B.; Druckman, R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm. Mol. Biol. Clin. Investig. 2018, 34. [Google Scholar] [CrossRef]
- Papaleo, E.; Unfer, V.; Baillargeon, J.-P.; De Santis, L.; Fusi, F.; Brigante, C.; Marelli, G.; Cino, I.; Redaelli, A.; Ferrari, A. Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. Gynecol. Endocrinol. 2007, 23, 700–703. [Google Scholar] [CrossRef]
- Papaleo, E.; Unfer, V.; Baillargeon, J.-P.; Fusi, F.; Occhi, F.; De Santis, L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil. Steril. 2009, 91, 1750–1754. [Google Scholar] [CrossRef]
- Raffone, E.; Rizzo, P.; Benedetto, V. Insulin sensitizer agents alone and in co-treatmentwithrFSH for ovulation induction in PCOS women. Gynecol. Endocrinol. 2010, 26, 275–280. [Google Scholar] [CrossRef]
- Ciotta, L.; Iozza, I.; Rubbino, G.; Iemmola, A.; Lizzio, I.; Teodoro, M.C.; Palumbo, M. Treatment of hyperandrogenism by myo-inositol. In Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy, 4–7 March 2010. [Google Scholar]
- Di Berardino, O.M.; Monteleone, P.; Valentino, V.; Ruggiero, M.; Papini, F.; Cela, V.; Artini, P.G.; Genazzani, A.R. Myo-inositol administration in pcos patients after IVF. In Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy, 4–7 March 2010. [Google Scholar]
- Kamenov, Z.; Kolarov, G.; Gateva, A.; Carlomagno, G.; Genazzani, A.D. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol. Endocrinol. 2015, 31, 131–135. [Google Scholar] [CrossRef]
- Papaleo, E.; De Santis, L.; Baillargeon, J.; Zacche, M.; Fusi, F.; Brigante, C.; Ferrari, A. Comparison of myo-inositol plus folic acid vs clomiphene citrate for first line treatment in women with polycystic ovary syndrome. In Proceedings of the 24th Annual Meeting of ESHRE, Barcelona, Spain, 6–9 July 2008. [Google Scholar]
- Morgante, G.; Orvieto, R.; Di Sabatino, A.; Musacchio, M.C.; De Leo, V. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil. Steril. 2011, 95, 2642–2644. [Google Scholar] [CrossRef]
- Gerli, S.; Mignosa, M.; Di Renzo, G.C. Effects of inositol on ovarian function and metabolic factors in women with PCOS: A randomized double blind placebo-controlled trial. Eur. Rev. Med. Pharmacol. Sci. 2004, 7, 151–159. [Google Scholar]
- Costantino, D.; Minozzi, G.; Minozzi, E.; Guaraldi, C. Metabolic and hormonal effects of myoinositol in women with polycystic ovarian syndrome: A double-blind trial. Eur. Rev. Med. Pharmacol. Sci. 2009, 13, 105–110. [Google Scholar]
- Regidor, P.-A.; Schindler, A.E. Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study. Int. J. Endocrinol. 2016, 2016, 1–5. [Google Scholar] [CrossRef]
- Le Donne, M.; Alibrandi, A.; Giarrusso, R.; Monaco, I.L.; Muraca, U. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: Effects on body composition. Minerva Ginecol. 2012, 64, 23. [Google Scholar]
- Bevilacqua, A.; Dragotto, J.; Giuliani, A.; Bizzarri, M. Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J. Cell. Physiol. 2018, 234, 9387–9398. [Google Scholar] [CrossRef]
- Nordio, M.; Basciani, S.; Camajani, E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: Comparison with other ratios. Eur Rev. Med. Pharmacol Sci. 2019, 23, 5512–5521. [Google Scholar]
- Mendoza, N.; Diaz-Ropero, M.P.; Aragon, M.; Maldonado, V.; Llaneza, P.; Lorente, J.; Mendoza-Tesarik, R.; Maldonado-Lobon, J.; Olivares, M.; Fonolla, J. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: A randomized controlled trial. Gynecol. Endocrinol. 2019, 8, 695–700. [Google Scholar] [CrossRef]
- Mendoza, N.; Galan, M.I.; Molina, C.; Mendoza-Tesarik, R.; Conde, C.; Mazheika, M.; Diaz-Ropero, M.P.; Fonolla, J.; Tesarik, J.; Olivares, M. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: A randomized controlled trial. Gynecol. Endocrinol. 2020, 36, 398–401. [Google Scholar] [CrossRef] [PubMed]
- Roseff, S.; Montenegro, M. Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary. Int. J. Endocrinol. 2020, 2020, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kjerulff, L.E.; Sanchez-Ramos, L.; Duffy, D. Pregnancy outcomes in women with polycystic ovary syndrome: A metaanalysis. Am. J. Obstet. Gynecol. 2011, 204, 558.e1–558.e6. [Google Scholar] [CrossRef] [PubMed]
- Mustaniemi, S.; Vääräsmäki, M.; Eriksson, J.G.; Gissler, M.; Laivuori, H.; Ijäs, H.; Bloigu, A.; Kajantie, E.; Morin-Papunen, L. Polycystic ovary syndrome and risk factors for gestational diabetes. Endocr. Connect. 2018, 7, 859–869. [Google Scholar] [CrossRef]
- Santamaria, A.; Di Benedetto, A.; Petrella, E.; Pintaudi, B.; Corrado, F.; D’Anna, R.; Neri, I.; Facchinetti, F. Myo-inositol may prevent gestational diabetes onset in overweight women: A randomized, controlled trial. J. Matern. Neonatal Med. 2015, 29, 3234–3237. [Google Scholar] [CrossRef]
- D’Anna, R.; Di Benedetto, A.; Scilipoti, A.; Santamaria, A.; Interdonato, M.L.; Petrella, E.; Neri, I.; Pintaudi, B.; Corrado, F.; Facchinetti, F. Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial. Obstet. Gynecol. 2015, 126, 310–315. [Google Scholar] [CrossRef] [Green Version]
- Matarrelli, B.; Vitacolonna, E.; D’Angelo, M.; Pavone, G.; Mattei, P.A.; Liberati, M.; Celentano, C. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: A randomized controlled trial. J. Matern. Neonatal Med. 2013, 26, 967–972. [Google Scholar] [CrossRef]
- D’Anna, R.; Di Benedetto, V.; Rizzo, P.; Raffone, E.; Interdonato, M.L.; Corrado, F. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol. Endocrinol. 2012, 28, 440–442. [Google Scholar] [CrossRef]
- Corrado, F.; D’Anna, R.; Di Vieste, G.; Giordano, D.; Pintaudi, B.; Santamaria, A.; Di Benedetto, A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet. Med. 2011, 28, 972–975. [Google Scholar] [CrossRef]
- Jamilian, M.; Farhat, P.; Foroozanfard, F.; Ebrahimi, F.A.; Aghadavod, E.; Bahmani, F.; Badehnoosh, B.; Jamilian, H.; Asemi, Z. Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. Clin. Endocrinol. 2017, 87, 194–200. [Google Scholar] [CrossRef]
- Genazzani, A. Expert’s opinion: Integrative treatment with inositols and lipoic acid for insulin resistance of PCOS. Gynecol. Reprod. Endocrinol. Metab. 2020, 1, 146–157. [Google Scholar]
- Cianci, A.; Panella, M.; Fichera, M.; Falduzzi, C.; Bartolo, M.; Caruso, S. Dchiro-inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol. Endocrinol. 2015, 31, 483–486. [Google Scholar] [CrossRef] [PubMed]
- Masharani, U.; Gjerde, C.; Evans, J.L.; Youngren, J.F.; Goldfine, I.D. Effects of Controlled-Release Alpha Lipoic Acid in Lean, Nondiabetic Patients with Polycystic Ovary Syndrome. J. Diabetes Sci. Technol. 2010, 4, 359–364. [Google Scholar] [CrossRef] [PubMed]
- Fruzzetti, F.; Capozzi, A.; Canu, A.; Lello, S. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. Gynecol. Endocrinol. 2019, 35, 506–510. [Google Scholar] [CrossRef]
- Artini, P.G.; Obino, M.E.R.; Micelli, E.; Malacarne, E.; Vacca, C.; Papini, F.; Cela, V. Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women. Gynecol. Endocrinol. 2020, 36, 755–759. [Google Scholar] [CrossRef]
- De Cicco, S.; Immediata, V.; Romualdi, D.; Policola, C.; Tropea, A.; Di Florio, C.; Tagliaferri, V.; Scarinci, E.; Della Casa, S.; Lanzone, A.; et al. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. Gynecol. Endocrinol. 2017, 33, 698–701. [Google Scholar] [CrossRef]
- Fruzzetti, F.; Fidecicchi, T.; Palla, G.; Gambacciani, M. Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. Gynecol. Endocrinol. 2020, 36, 152–155. [Google Scholar] [CrossRef]
- Fruzzetti, F.; Benelli, E.; Fidecicchi, T.; Tonacchera, M. Clinical and Metabolic Effects of Alpha-Lipoic Acid Associated with Two Different Doses of Myo-Inositol in Women with Polycystic Ovary Syndrome. Int. J. Endocrinol. 2020, 2020, 2901393. [Google Scholar] [CrossRef]
- Genazzani, A.D.; Prati, A.; Marchini, F.; Petrillo, T.; Napolitano, A.; Simoncino, T. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/ obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. Gynecol. Endocrinol. 2019, 35, 1088–1093. [Google Scholar] [CrossRef]
- Cirillo, F.; Catellani, C.; Lazzeroni, P.; Sartori, C.; Tridenti, G.; Vezzani, C.; Fulghesu, A.M.; Madeddu, E.; Amarri, S.; Street, M.E. HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA). Gynecol. Endocrinol. 2020, 36, 588–593. [Google Scholar] [CrossRef]
- Advani, K.; Batra, M.; Tajpuriya, S.; Gupta, R.; Saraswat, A.; Nagar, H.D.; Makwana, L.; Kshirsagar, S.; Kaul, P.; Ghosh, A.K.; et al. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: An observational study. J. Obstet. Gynaecol. 2019, 40, 96–101. [Google Scholar] [CrossRef] [PubMed]
- Oliva, M.M.; Zuev, V.; Lippa, A.; Carra, M.C.; Lisi, F. Efficacy of the synergic action of myoinositol, tyrosine, selenium and chromium in women with PCOS. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 8687–8694. [Google Scholar]
- Troisi, J.; Cinque, C.; Giugliano, L.; Symes, S.; Richards, S.; Adair, D.; Cavallo, P.; Sarno, L.; Scala, G.; Caiazza, M.; et al. Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: A pilot study. J. Ovarian Res. 2019, 12, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pacchiarotti, A.; Carlomagno, G.; Antonini, G.; Pacchiarotti, A. Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol. Endocrinol. 2016, 32, 69–73. [Google Scholar] [CrossRef] [PubMed]
- Wdowiak, A.; Filip, M. The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: A randomized prospective controlled trial. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 8529–8536. [Google Scholar] [PubMed]
- Kamenov, Z.; Gateva, A. Inostol resistance—A problem and a solution. In Inositols—Guide to Practical Applications in Obstetrics and Gynecology; Unfer, F., Ed.; A.G.UN.CO Obstetrics and Gynecology Center: Rome, Italy, 2020; pp. 109–124. ISBN 9781536149128. [Google Scholar]
- Oliva, M.M.; Buonomo, G.; Calcagno, M.; Unfer, V. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J. Ovarian Res. 2018, 11, 38. [Google Scholar] [CrossRef] [PubMed]
Dosage | Effects on Metabolic Abnormalities | Effects on Hyperandrogenism | Effect on Menstrual Cyclicity/Ovulation | |
---|---|---|---|---|
MI | 1200–4000 mg daily [77,78,81] |
|
|
|
DCI | 1200 mg daily [68] |
|
| |
MI + DCI 40:1 | 550 mg + 13.8 mg daily [92,93,94] |
|
|
|
MI + DCI in other ratios | 10:1—500 mg + 50 mg [95] 0:1; 1:3.5; 2.5:1; 5:1; 20:1; 80:1 (total daily dose 2000 mg) [112] 2:1 (500 mg + 300 mg) [114] 3:1 (550 mg+150 mg) |
|
|
|
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kamenov, Z.; Gateva, A. Inositols in PCOS. Molecules 2020, 25, 5566. https://doi.org/10.3390/molecules25235566
Kamenov Z, Gateva A. Inositols in PCOS. Molecules. 2020; 25(23):5566. https://doi.org/10.3390/molecules25235566
Chicago/Turabian StyleKamenov, Zdravko, and Antoaneta Gateva. 2020. "Inositols in PCOS" Molecules 25, no. 23: 5566. https://doi.org/10.3390/molecules25235566